Kolon Life Science

Kolon Life Science EBIT per Share

The EBIT per Share of Kolon Life Science (102940.KQ) as of Nov 3, 2026 is 2,596.18 KRW. In the previous year, EBIT per Share was -2,413.76 KRW — a change of -207.56% (higher).

EBIT per Share

2,596.18KRW

YoY

-207.56%

Last updated:

EBIT per Share of Kolon Life Science is 2025 2,596.18 KRW. EBIT per Share of Kolon Life Science was 2024 -2,413.76 KRW. It decreases by -207.56% higher compared to the previous year.

The Kolon Life Science EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2017
-729.31 KRW
Jan 1, 2018
-4,563.52 KRW
Jan 1, 2019
-2,522.26 KRW
Jan 1, 2020
-3,316.84 KRW
Jan 1, 2021
-39.79 KRW
Jan 1, 2022
688.93 KRW
Jan 1, 2023
-2,413.76 KRW
Jan 1, 2025
2,596.18 KRW
The Kolon Life Science EBIT per Share history
YEAREBIT per ShareYoY
2,596.18KRW-207.56%
-2,413.76KRW-450.36%
688.93KRW-1,831.47%
-39.79KRW-98.80%
-3,316.84KRW+31.50%
-2,522.26KRW-44.73%
-4,563.52KRW+525.73%
-729.31KRW-145.45%
1,604.77KRW+635.21%
218.27KRW-76.77%
939.55KRW-48.77%
1,834.00KRW+39.60%
1,313.75KRW-18.92%
1,620.25KRW+38.79%
1,167.43KRW+96.49%
594.14KRW-21.05%
752.60KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kolon Life Science Stock analysis

What does Kolon Life Science do? KOLON Life Science, Inc. generates revenue through its Chemical Business segment, which produces and sells raw drug products, antibacterial agents, water treatment agents, and functional material products for cosmetics. The Bio Business segment focuses on manufacturing and selling bio new medicines based on cell gene therapy products. The company's products target pharmaceutical and environmental markets, with raw drug products serving as essential components for new and generic drugs, while antibacterial agents and water treatment agents address healthcare and environmental purification needs. Functional materials for cosmetics represent a key product line within the Chemical Business segment. The company's revenue streams are derived from the sale of pharmaceutical raw materials, antibacterial agents, water treatment solutions, and cosmetic functional materials under the Chemical Business segment. The Bio Business segment contributes through the commercialization of advanced cell gene therapy-based medicines. Both segments operate within the pharmaceutical and environmental sectors, with the Chemical Business serving as the primary revenue driver for raw materials and environmental products, while the Bio Business targets innovative therapeutic solutions in the biopharmaceutical space. KOLON Life Science, Inc. sells its products to the pharmaceutical industry for drug development and manufacturing, as well as to environmental and cosmetic companies requiring specialized materials. The Chemical Business segment's raw drug products are used by pharmaceutical firms to produce new and generic drugs, while antibacterial agents and water treatment agents are supplied to healthcare and environmental purification sectors. Cosmetic functional materials are sold to the cosmetics industry for product development. The Bio Business segment's cell gene therapy products are targeted at biopharmaceutical companies seeking advanced treatment options. Kolon Life Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kolon Life Science stock

EBIT per Share of Kolon Life Science is 2,596.18 KRW in 2025.

EBIT per Share of Kolon Life Science changed from -2,413.76 KRW to 2,596.18 KRW, representing a -207.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Kolon Life Science since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Kolon Life Science

All Key Metrics — Kolon Life Science